Portal hypertensive gastropathy (PHG) is a serious complication of liver cirrhosis and a potential cause of bleeding in patients with cirrhosis. Suppressed mucosal epithelial proliferation is a crucial pathological characteristic of PHG. Our studies demonstrated an important role for PGE 2 and its EP 4 receptor in the promotion of mucosal proliferation. However, whether β-arrestin1 (β-arr1), a well-established mediator of GPCRs, is involved in the PGE 2 /EP 4 receptor-mediated mucosal proliferation complex in PHG remains unclear. The aim of the study was to investigate whether β-arr1 participated in PGE 2 /EP 4 receptor-mediated mucosal proliferation by recruiting the Src/EGF receptor (EGFR) complex to activate Akt/proliferating cell nuclear antigen (PCNA) signalling in PHG.
Introduction
Portal hypertensive gastropathy (PHG) is clinically important because it is a potential cause of gastric haemorrhage in patients afflicted with portal hypertension (McCormack et al., 1985; Cubillas and Rockey, 2010; Massoni et al., 2016) . Numerous elements, such as portal hypertension, PGs, TNF-α and NO, have been demonstrated to participate in the pathogenesis of PHG (Patwardhan and Cardenas, 2014; Gjeorgjievski and Cappell, 2016) . Gastric mucosal apoptosis is involved in PHG, and p53-up-regulated modulator of apoptosis (PUMA) plays a vital role in endoplasmic reticulum (ER) stress-induced mucosal epithelial apoptosis in PHG (Tan et al., 2014) . Moreover, a mediator of GPCRs, β-arrestin1 (β-arr1), regulates ER stress/PUMA-induced mucosal epithelial apoptosis by suppressing the activation of the TNF-α/p65/iNOS signalling pathway in PHG . However, the role of mucosal proliferation in the pathogenesis of this disorder has not been fully explored.
Our previous and other research revealed that PGs, specifically PGE 2 , produced via COX-1, play a key role in the protection of the gastric mucosa from injury and apoptosis in PHG (Wu et al., 2009; Norregaard et al., 2015) . The primary enzyme responsible for PGE 2 synthesis, COX, exists as three major isoforms. COX-1 is constitutively active and present within the gastrointestinal tract. COX-2 is largely restricted to the kidney as well as in areas of the CNS. COX-3 is a critical mediator of the generation of anti-inflammatory and analgesic agents (Greenhough et al., 2009; Wu et al., 2009) .
The physiological activity of PGE 2 is mediated by the activation of a diverse group of downstream signalling cascades via GPCRs, referred to as EP receptors: EP 1 , EP 2 , EP 3 and EP 4 (Kim et al., 2010; Yokoyama et al., 2013) . It has been proposed that the activity of GPCRs is regulated by receptor internalization/desensitization following the formation of a complex with β-arrestins (β-arr1 and β-arr2). β-arrestins have been identified to serve as scaffolds to link receptors to downstream signalling pathways, such as MAPKs, Src, EGF receptor (EGFR) (Shenoy, 2014; Shukla et al., 2014) , and are crucial in the pathogenesis of numerous diseases, including multiple sclerosis, PHG, hepatocellular carcinogenesis and colitis (Shukla et al., 2011; Tan et al., 2015; Yang et al., 2015) . PGE 2 stimulation of EP 4 receptors induces the formation of an EP 4 receptor-β-arr1-Src complex, which could result in Src activation and the transactivation of EGFRs that can then enhance cell proliferation and differentiation (Kim et al., 2010; Yokoyama et al., 2013) . Previously, we found that portal hypertension suppressed gastric mucosal COX-1 and PGE 2 , and ultimately inhibited cellular proliferation and promoted mucosal apoptosis, suggesting that PGE 2 plays an important role in the mucosal proliferation of PHG (Wu et al., 2009) . However, how PGE 2 contributes to mucosal proliferation of PHG remains poorly understood.
In the current study, we found that COX-1, which is associated with PGE 2 generation and the level of expression of EP 4 receptors, was suppressed in the mucosa of PHG. The EP 4 receptor was investigated because preliminary studies utilizing EP 1 , EP 2 , EP 3 and EP 4 receptor antagonists indicated that the EP 4 receptor plays an important role in mucosal proliferation in mice with PHG following PGE 2 treatment. Furthermore, PGE 2 recruited the β-arr1/Src/EGFR complex to the EP 4 receptor, which markedly ameliorated mucosal apoptosis and enhanced cellular proliferation in PHG via the Akt/PCNA signalling pathway. These results indicate that β-arr1 regulates PGE 2 /EP 4 receptor-mediated mucosal proliferation by promoting activation of Src/EGFR/Akt/PCNA signalling pathway, and this network could be a potential therapeutic target for PHG.
Methods

Tissue samples
Frozen randomized gastric mucosal tissues of 15 patients with PHG without Helicobacter pylori infection and 15 uninvolved, 
Mice and induction of portal hypertension
All animal experiments were approved by the Institutional Animal Care and Use Committee at Sun Yat-Sen University. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . A total of 210 mice were used. Eight-to ten-week-old male mice (20-25 g) were housed in microisolator cages in a room illuminated from 08:00 h to 20:00 h [12:12 h light : dark cycle; a climatically controlled environment (22 ± 2°C)] and were allowed access to water and chow ad libitum. β-arr1 wild type (β-arr1-WT) and β-arr1 knockout (β-arr1-KO) littermates on C57BL/6 background were generated from heterozygote intercrosses (Provided by Dr R. J. Lefkowitz, Duke University Medical Centre, Durham, NC, USA). The mouse cages (U-TEMP Polyetherimide, Techniplast, UK) were 820 cm 2 by 15.5 cm depth, and bedding was supplied from the Institutional Animal Care and Use Committee at Sun YatSen University. All experiments were conducted in a blinded manner, and mice were randomly allocated to the indicated groups. The experimenter was blinded to the treatment or genetic background at the time of the experiments. At the end of the experiments, all mice were killed by cervical dislocation. Portal hypertension was induced by constricting the portal vein, as previously described . The portal vein was isolated, and a standardized constriction was performed using a single ligature of 3-0 silk around the portal vein and a 20-gauge blunt-tipped needle under halothane anaesthesia. The needle was then removed, leaving a calibrated stenosis of the portal vein. This technique involved the initial constriction of the portal vein to approximately 50% of its diameter. The same operation was performed in sham operation (SO) mice with the exception that no ligation was performed after isolating the portal vein. After the above-mentioned operation, all the mice were housed in cages until the experiments were performed after 2 weeks and they were killed by cervical dislocation under halothane anaesthesia. 
Collection of gastric mucosa
The collection of gastric mucosa was performed as previously described . The mouse was anaesthetized, and the entire stomach was carefully removed and rinsed thoroughly with physiological saline and then opened on its lesser curvature longitudinally to expose the gastric mucosa. The mucosal layers were harvested and stored at À80°C before analysis. To prepare paraffin sections, the stomach was fixed in 10% neutral buffered formalin before embedding. The concentration of PGE 2 was analysed by using an ELISA kit (Roche, Switzerland) according to the manufacturer's instructions.
Histological and TUNEL staining
Histological and TUNEL analysis was performed on formalin fixed tissues embedded in paraffin as previously described (Tan et al., 2014) . TUNEL staining was performed using an in situ cell death detection kit according to the manufacturer's instructions. The apoptotic index was determined by dividing the number of apoptotic cells by the total number of cells in the mucosa of at least 20 randomly selected fields, and the proliferation index was also performed using similar methods as those used to obtain the apoptotic index (Tan et al., 2014) . Six mice or human sections were studied in each group. Specified mice were anaesthetized, and the entire stomach was carefully removed and rinsed thoroughly with physiological saline and then opened on its lesser curvature longitudinally to expose the gastric mucosa, and the gastric injury index was assessed blindly based on previously described criteria: 0 = normal; 1 = mucosa with erosion; 2 = mucosa with ulcer (<1 mm); 3 = mucosa with ulcer (1-2 mm); 4 = mucosa with ulcer (3-4 mm); and 5 = mucosa with ulcer (>5 mm).
Immunohistochemical staining, immunofluorescence staining
For immunohistochemical (IHC) staining, 4 μm frozen sections were fixed with 4% paraformaldehyde for 15 min after being dewaxed, then permeabilized with 1% Triton X-100 for 30 min and washed three times with PBS. The targeted protein was then revealed using secondary antibodies followed by detection using the ABC staining system, and the sections were counterstained with haematoxylin. For immunofluorescence (IF) staining, the targeted proteins were detected by related secondary antibody. Antibody-antigen complexes were visualized by incubation with biotin-conjugated secondary antibody and . For controlling unwanted sources of variation, each sample was normalized to the β-actin gene in the same sample.
Co-immunoprecipitation
Co-immunoprecipitation was done using the Thermo Scientific Pierce Co-immunoprecipitation kit following the manufacturer's protocol (Thermo Scientific, Rockford, AL, USA). The entire stomach was carefully removed and rinsed, the pylorus ligated and then the cardia was perfused through with Ca 2+ -free HBSS for 15 min, with 100 mL 0.2% pronase solution and with 0.2% collagenase type-IV (Sigma) solution. The mucosal layers were harvested for cells suspension and then filtered through 100 μm pore size mesh nylon filter (Sinopharm Chemical Reagent, Shanghai, China). The cells were centrifuged at 300× g for 15 min, and the pellet was collected for the isolation of gastric epithelial cells. Commercially available 30% Percoll (Sigma) was prepared, and the above-mentioned pellet was added to the upper layer of Percoll carefully and then was centrifuged at 450× g for 20 min; the pellet was lysed in RIPA buffer (Gibco BRL, Rockville, MD, USA) with protease inhibitor cocktail for gastric epithelial lysis. Immunoprecipitating antibody (4 μg, as shown above) or normal IgG (negative control, Santa Cruz) was added and then incubated on a rotator at 4°C overnight. The 25 μL G/A agarose beads were added into the 200 μL lysates and incubated for 3 h with gentle agitation at room temperature. The beads were rinsed five times using the indicated lysis buffer and boiled with 10 μL indicated 2× sample buffer according to the manufacturer's instructions. The beads were removed by centrifugation at 14 000 × g for 10 min, and the final samples were analysed by western blotting using the indicated antibodies.
Statistical analysis
All the experiments were repeated at least five times with similar results. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . The data are expressed as the mean ± SEM, and statistical analyses were performed using Student's two-tailed paired t-test or one-way ANOVA (more than two groups of data, single factor) or two-way ANOVA (more than two groups of data, two factors), followed by Bonferroni's comparison post hoc test; post hoc tests were run only if F achieved P < 0.05 and there was no significant variance inhomogeneity. Differences were considered statistically significant if the probability of the difference occurring by chance was less than 5 in 100 (P < 0.05).
Results
COX-1 and PGE 2 are suppressed in PHG
Previously, we reported that portal hypertension suppressed gastric mucosal COX-1 expression and increased gastric mucosal apoptosis. In the current study, we found that COX-1, but not COX-2, was markedly suppressed in the tissues of patients with PHG compared with that of healthy volunteers ( Figure 1A ), and western blotting analysis further revealed that COX-1, but not COX-2, was down-regulated in PHG sections ( Figure 1B , E). Based on these results, we explored whether COX-1 expression was also repressed by portal hypertension in animals. The portal hypertension mouse model, induced by partial portal vein ligation (PVL) for 2 weeks, was used. IHC staining revealed that the expression of COX-1 was down-regulated in PVL-treated mice, while that of COX-2 was not affected ( Figure 1C ). These findings were confirmed by western blotting results (Figure 1 D, F). COXs are primarily responsible for PGE 2 synthesis, and our previous research demonstrated that COX-1-derived PGE 2 contributed to the gastric mucosal defence in PHG (Wu et al., 2009) . In this study, we found that PGE 2 concentrations in PHG patient tissues were lower than those of tissue samples from the control group (uninvolved; Figure 1G ). Using the PVL-treated model, consistent with patients with PHG, the induction of PGE 2 in the mucosa of the PVL-treated mouse model was also markedly downregulated ( Figure 1H ). From these studies, we concluded that COX-1, but not COX-2, was suppressed in PHG and that PGE 2 might participate in the pathogenesis of PHG.
PGE 2 attenuates mucosal injury by promoting proliferation in PHG
Based on the finding that PGE 2 may be involved in the development of PHG, exogenous PGE 2 was used to investigate the role of PGE 2 in the gastric mucosa of PHG. After 2 weeks of partial portal ligation, a loss of preserved architecture, oedema, vasodilatation with the infiltration of inflammatory cells and a significantly down-regulated
Figure 1
COX-1 and PGE 2 are suppressed in PHG. (A) COX-1 and COX-2 IHC staining of uninvolved normal gastric mucosal tissue (from healthy volunteers) and gastropathic mucosal tissue from PHG patients (brown, ×400, n = 6 per group). (B) COX-1 and COX-2 levels in the gastric mucosa were determined by western blotting in three pairs of different representative specimens; β-actin was used as the loading control (n = 6 per group).
(C) COX-1 expression was repressed in mice gastric mucosal after PVL for 2 weeks, while COX-2 was not affected (brown, ×400, n = 6 per group).
(D) The levels of COX-1 and COX-2 in the representative gastric mucosa were determined by western blotting; β-actin was used as the loading control (n = 6 per group). (E) and (F) The ratio of densitometry units of the normalized COX-1/β-actin and COX-2/β-actin was analysed from the western blotting assay (values are expressed as mean ± SEM, n = 6 per group, Bonferroni's comparison post hoc test (Figure 2A , B). Gastric mucosal cellular proliferation was evaluated by assessing Ki-67 (a nuclear protein associated with cellular proliferation). After 2 weeks of partial portal ligation, the expression of gastric mucosal Ki-67 was obviously inhibited, and quantitative analysis showed that the proliferation index was reduced compared with SO mice. Interestingly, treatment with PGE 2 alleviated the repression of mucosal proliferation due to portal hypertension ( Figure 2C , E). TUNEL analysis of gastric mucosa showed that few apoptotic cells were observed at the top of pits of SO mice or PGE 2 -treated mice. Compared with these findings, a significant increase in the number of apoptotic cells was observed in PVL-treated mice, while
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Figure 2
PGE 2 attenuates mucosal injury by promoting proliferation in PHG. (A) Gastric mucosal injury was significantly attenuated in PVL mice with PGE 2 treatment (H&E staining, ×200, n = 6 per group). (B) PGE 2 administration (3 mg·kg À1 ) up-regulated the expression of the PGE 2 receptor EP 4 in the gastric mucosa of PVL-treated mice (red, ×400). Cell nuclei (blue) were counterstained with DAPI (n = 6 per group). (C) PGE 2 administration (3 mg·kg À1 ) promoted cell proliferation in the gastric mucosa of PVL-treated mice, as determined by immunohistochemical staining for Ki-67 (a nuclear protein associated with cellular proliferation) (brown, ×200, n = 6 per group). (D) Immunofluorescence staining for β-arr1 (red) with DAPI counterstaining for DNA (blue) in the indicated sections from PVL-treated mice with or without PGE 2 (3 mg·kg À1 ) (×400, n = 6 per group). (E) The gastric injury index (left panel) was represented based on the criteria from the Methods section. The proliferation index (right panel) was calculated by enumerating the proliferative cells in a minimum of 20 randomly selected fields and dividing the number of Ki-67-positive cells by the total number of cells. Values are expressed as mean ± SEM (n = 6 per group). *P < 0.05 versus SO (control) mice, #P < 0.05 versus PVL-treated mice with PGE 2 administration (3 mg·kg À1 ). (F) Western blotting demonstrated that PGE 2 administration (3 mg·kg À1 ) suppressed the expression of cleaved caspase-3 and up-regulated the levels of EP 4 receptors, β-arr1 and PCNA in PVL-treated mice. β-actin was used as the loading control, n = 6 per group.
PGE 2 administration in PHG mice markedly reduced the number of apoptotic cells induced by portal hypertension (Supporting Information Figure S1A , B). Furthermore, western blotting detection also provided similar findings ( Figure 2F , Supporting Information Figure S1 ). Our previous results indicated that the well-established endocytic mediator of GPCRs, β-arr1, may be involved in the regulation of ER stress/PUMA-induced gastric injury and apoptosis in PHG, and β-arr1 was increased in patients with PHG as well as mouse models of PHG. On the basis of these findings, immunofluorescence staining and western blotting analyses were performed and revealed that the expression of β-arr1 was increased in PVL-treated mice. These findings were consistent with a reduction in the proliferative protein PCNA. However, PGE 2 treatment markedly increased both the levels of β-arr1 and PCNA in the mucosa of PHG, which might contribute to the mucosal proliferation of PHG ( Figure 2D, F) . Thus, PGE 2 , by inhibiting mucosal apoptosis, is a crucial protector of gastric mucosa, which is consistent with the enhancement of mucosal proliferation in PHG, and thus, β-arr1 might play a distinct role in the mucosal proliferation of PHG.
PGE 2 promotes proliferation via the EP 4 receptor in PHG
We found that PGE 2 attenuated mucosal injury by promoting proliferation in PHG, and it has been demonstrated that PGE 2 performs its biological activities by binding to the GPCRs: EP 1 , EP 2 , EP 3 and EP 4 receptors (Han and Wu, 2015; Sokolowska et al., 2015) . To evaluate the definite receptor that PGE 2 interacts with in PHG, the indicated gastric specimens were analysed using real-time PCR. We revealed that the levels of the EP 4 receptor were significantly suppressed in the gastric mucosa in both PHG patients and PVL-treated mice ( Figure 3A, B Figure 3C, D) . Moreover, western blotting analysis of gastric sections also showed that the EP 4 antagonist could suppress the expression of the proliferative protein PCNA induced by PGE 2 in PHG ( Figure 3E, F) . Furthermore, histopathological and western blotting analysis of gastric sections also demonstrated that EP 4 receptors were repressed in PHG ( Figure 3G , H). Taken together, these results suggested that the EP 4 receptor plays a crucial role in PHG and that PGE 2 promotes mucosal proliferation via the EP 4 receptor in PHG.
Targeted deletion of β-arr1 blocks PGE 2 /EP 4 receptor-mediated mucosal proliferation in PHG
Based on the involvement of β-arr1 in PGE 2 /EP 4 receptormediated mucosal proliferation, β-arr1-WT and β-arr1-KO mouse models of PHG were used to investigate the status of β-arr1 in the network of PGE 2 /EP 4 receptor signalling in PHG. Histopathological analysis showed marked gastric damage with mucosal erosion and a reduced number of Ki-67-positive cells in PVL-treated β-arr1-KO mice compared with WT mice. However, the destruction of the normal architecture by oedema and vasodilatation was significantly attenuated in the gastric mucosa of β-arr1-WT mouse models following PGE 2 treatment, but PGE 2 did not alleviate the mucosal injury and enhance proliferation in PVL-treated β-arr1-KO mice ( Figure 4A, C) .
To confirm the effect of β-arr1 on mucosal apoptosis in PHG with PGE 2 administration, TUNEL staining was performed to determine the location and percentage of apoptotic cells in situ. Many TUNEL-positive cells were detected in the gastric mucosa of PVL-treated mice, and mucosal apoptosis was significantly exacerbated in the β-arr1-KO mice, with an apoptotic index that was higher following PVL treatment compared with β-arr1-WT mice ( Figure 4B, D) . PGE 2 treatment attenuated mucosal apoptosis in β-arr1-WT PHG mice but not in β-arr1-KO PHG mice. Furthermore, PGE 2 administration enhanced the level of EP 4 receptors, irrespective of β-arr1 deletion, although EP 4 receptor protein levels were significantly suppressed in both PVL-treated β-arr1-WT and β-arr1-KO mice ( Figure 4E) . Consistent with the histological analysis, western blotting analyses demonstrated that the increase in EP 4 receptors and PCNA in the mucosa of PVL-treated mouse models was markedly down-regulated, while targeted deletion of β-arr1 enhanced the expression of cleaved caspase-3 and inhibited PCNA expression, without affecting the level of EP 4 receptors. In addition, PGE 2 administration markedly promoted the expression of β-arr1 and PCNA in WT PHG mice, although the level of EP 4 receptors were up-regulated in PHG mice of both genotypes ( Figure 4F, G) . Taken together, these observations demonstrate that β-arr1, as a downstream element, plays a critical role in PGE 2 /EP 4 receptor-mediated gastric mucosal proliferation in PHG and that targeted deletion of β-arr1 blocks PGE 2 -mediated mucosal proliferation in PHG.
PGE 2 /EP 4 receptor promotes Src and EGFR activation and complex formation via β-arr1 in PHG As a multifunctional cellular mediator, β-arr1 is a wellestablished moderator of the endocytosis of GPCRs, ubiquitination and G-protein-independent signalling, and it has been demonstrated that the GPCR-β-arr1 complex has more biological functions than desensitization, as the complex could also contribute to receptor-mediated signalling, including the activation of Src, EGFR, ERK 1/2, MAPKs and PI3K (Shukla et al., 2014; Thomsen et al., 2016) . Indeed, it was demonstrated in an in vitro study that PGE 2 stimulation of EP 4 receptors could cause the formation of an EP 4 receptor-β-arr1-Src complex that led to Src activation and EGFR transactivation (Konya et al., 2013) .
To evaluate the role of β-arr1 in PGE 2 /EP 4 receptormediated gastric mucosal proliferation in PHG, gastric mucosal specimens from PHG patients and healthy volunteers were analysed. IHC staining showed that the expression levels of the active forms of EGFR and Src, p-EGFR and p-Src, were markedly decreased in PHG mucosa compared with normal mucosa, and these findings were also confirmed by western blotting analyses ( Figure 5A-D) , revealing that the activation of EGFR and Src was blocked during the process of PHG. Furthermore, using β-arr1-WT BJP S Tan et al. The levels of the four PGE 2 receptors (EP: EP 1 , EP 2 , EP 3 , and EP 4 ) in the gastric mucosa were evaluated by real-time PCR. Relative mRNA levels were analysed by real-time PCR following the normalization of cellular β-actin mRNA levels. n = 6 in each group, values are presented as mean ± SEM, *P < 0.05 versus the EP 4 levels of the uninvolved group (healthy volunteers) or SO (control) mice. Bonferroni's comparison post hoc test. (C) Immunohistochemical staining for PCNA in PVL-treated WT mice administered PGE 2 (3 mg·kg À1 ) by using the following: ONO-8713 (EP 1 antagonist), TG4-155 (EP 2 antagonist), ONO-AE5599 (EP 3 antagonist), and ONO-AE3-208 (EP 4 antagonist). n = 6 in each group. (D) The proliferation index was calculated from PCNA staining. Values are expressed as mean ± SEM (n = 6 per group). *P < 0.05 versus mice from the other groups. (E) The levels of cleaved caspase-3 and PCNA from the mice treated as indicated were represented by western blotting. β-actin was used as the loading control, n = 6 per group. (F) The ratio of densitometry units of the normalized PCNA/β-actin and cleaved caspase-3/β-actin was analysed from western blotting assay. n = 6 per group, *P < 0.05 versus mice from the other groups. Bonferroni's comparison post hoc test. (G) and (H) Immunohistochemical staining revealed that portal hypertension repressed the expression of EP 4 receptors in the gastric mucosal tissues from PHG patients and PVL mice respectively (upper panel, brown, ×400). The expression of EP 4 receptors in the gastric mucosa was determined by western blotting in three pairs of different representative samples (lower panel). β-actin was used as the loading control (n = 6 per group).
Figure 4
Targeted deletion of β-arr1 blocks PGE 2 /EP 4 receptor-mediated mucosal proliferation in PHG. (A) Gastric mucosal proliferation was repressed in β-arr1-KO mice after PVL, compared with β-arr1-WT mice. PGE 2 administration (3 mg·kg À1 ) significantly up-regulated Ki-67 (a nuclear protein associated with cellular proliferation) expression in the gastric mucosa of PVL-treated β-arr1-WT, without affecting that of β-arr1-KO mice (brown, ×200, n = 6 per group). (B) The number of apoptotic cells in the gastric mucosa was increased in β-arr1-KO mice after PVL compared with that in β-arr1-WT mice. PGE 2 treatment (3 mg·kg À1 ) attenuated apoptosis in the gastric mucosa of PVL-treated β-arr1-WT mice (green, ×400, n = 6 per group). (C) The proliferation index was analysed as described previously. *P < 0.05 versus PVL with vehicle mice, #P < 0.05 versus PVL-treated WT mice with PGE 2 administration (3 mg·kg À1 ). n = 6 per group. (D) The apoptotic index was analysed as described previously. *P < 0.05 versus PVL with vehicle mice, #P < 0.05 versus PVL-treated WT mice with PGE 2 administration (3 mg·kg À1 ). n = 6 per group. (E) Immunofluorescence staining for EP 4 receptors (red) with DAPI (blue) counterstaining for DNA in the indicated sections from PVL-treated β-arr1-WT and -KO mice, with or without PGE 2 treatment (×400, n = 6 per group). (F) Western blotting was adopted to analyse the expression of cleaved caspase-3, EP 4 receptors and PCNA. β-actin was used as the loading control. n = 6 per group. (G) The ratio of densitometry units of the normalized EP 4 /β-actin, cleaved caspase-3/β-actin and PCNA/β-actin was represented from western blotting. Values are expressed as mean ± SEM (n = 6 per group, Bonferroni's comparison post hoc test). *P < 0.05 versus PVL with vehicle mice, #P < 0.05 versus PVL-treated WT mice with PGE 2 administration (3 mg·kg À1 ).
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and β-arr1-KO mouse models of PHG with or without PGE 2 treatment, we demonstrated that the expression of p-EGFR and p-Src in β-arr1-WT and β-arr1-KO mice treated with PVL was significantly reduced, and that PGE 2 could up-regulate the levels of p-EGFR and p-Src in PVL-treated β-arr1-WT mice ( Figure 5E, F) . These results were also confirmed by western blotting analyses ( Figure 6A-C) . Next, we investigated whether Src and EGFR interacted with β-arr1 in PHG mice with or without PGE 2 treatment. As expected, the interaction between β-arr1 and Src-EGFR was determined in tissues from PVL-treated WT mice. However KO mice treated with PGE 2 showed no interaction ( Figure 6D ). The mucosal lysates of Figure 5 Src and EGFR activations are suppressed in PHG. (A) Immunohistochemical staining for p-EGFR and p-Src from the representative uninvolved normal gastric mucosal tissue (from healthy volunteers) and gastropathic mucosal tissue from PHG patients is presented (brown, ×400, n = 6 per group). (B) Western blotting showed that p-Src and p-EGFR were repressed in PHG sections (n = 6 per group). (C) and (D) The ratio of the normalized p-Src/β-actin and p-EGFR/β-actin was represented from western blotting (n = 6 per group, Bonferroni's comparison post hoc test). (E) Immunofluorescence staining for p-EGFR (red) with DAPI (blue) counterstaining for DNA in the indicated representative sections from PVLtreated β-arr1-WT and β-arr1-KO mice, with or without PGE 2 treatment (3 mg·kg À1 ) (×400, n = 6 per group). (F) Immunofluorescence staining of p-Src (red) was presented in the representative gastric mucosa of PVL-treated mice; nuclei (blue) were counterstained with DAPI (×400, n = 6 per group).
PVL-treated β-arr1-WT and -KO mice treated with PGE 2 were immunoprecipitated with an anti-Src antibody and then exposed to anti-EGFR and anti-β-arr1 antibodies; the results revealed a definite mutual effect between β-arr1 and Src/EGFR ( Figure 6E ). Moreover, using anti-EGFR antibody to immunoprecipitate the specific lysates, we obtained similar β-actin was used as the loading control. n = 6 per group. (B) and (C) The ratio of densitometry units of the normalized p-Src/β-actin and p-EGFR/β-actin (EGFR) was represented from western blotting (n = 6 per group, Bonferroni's comparison post hoc test). *P < 0.05 versus PVL with vehicle mice, #P < 0.05 versus PVL-treated WT mice with PGE 2 administration (3 mg·kg À1 ). (D) The representative gastric epithelial lysates from the relative β-arr1-WT and -KO mice were immunoprecipitated with anti-β-arr1 antibody and then analysed by anti-Src and anti-EGFR antibodies respectively. n = 6 per group. (E) Gastric epithelial lysates from the indicated representative sections were immunoprecipitated with anti-Src antibody and then analysed by anti-β-arr1 and anti-EGFR antibodies respectively. n = 6 per group. (F) The representative mucosal epithelial lysates from the mice indicated were immunoprecipitated with anti-EGFR antibody and then analysed by anti-Src and anti-β-arr1 antibodies respectively. n = 6 per group.
results ( Figure 6F ). Taken together, these results suggested that Src and EGFR activation are suppressed in PHG and that β-arr1 interacts with the Src/EGFR core complex in the presence of PGE 2 in PHG.
Inhibition of Src or EGFR blocks the PGE 2 /EP 4 receptor-induced mucosal proliferation in PHG
The upstream and downstream relationship between Src and EGFR in PGE 2 /EP 4 receptor-mediated signalling via β-arr1 still remains unclear. Pathological assays revealed that treatment with the Src inhibitor, PP2 of PVL-treated β-arr1-WT after PGE 2 administration markedly inhibited the activation of Src and EGFR. However, PP2 treatment did not inhibit the activation of Src and EGFR in PVL-induced β-arr1-KO mice treated with PGE 2 ; this may be due to the very few proteins being measured, such as activated Src and EGFR, which were detected in β-arr1-KO PHG mice, regardless of the addition of PGE 2 ( Figure 7A , G). Consistent with these findings, immunostaining and immunoblotting of PCNA showed that decreased positive signals were detected in WT mice with PP2 compared with that without PP2 ( Figure 7C , E). These findings reveal that Src is a crucial upstream regulator of EGFR signalling in the PGE 2 /EP 4 receptor-mediated response in PHG. Further analysis using the EGFR inhibitor AG1478 demonstrated that AG1478 inhibited EGFR activation, blocked PCNA up-regulation and decreased the mucosal proliferation mediated by PGE 2 in PHG WT mice. As expected, inhibition of EGFR with AG1478 had no effect on Src activation or the increase in β-arr1 and EP 4 receptors in PHG mice but reduced PGE 2 -mediated mucosal proliferation and repair in PHG ( Figure 7B, D, F, H) , further demonstrating that EGFR, as the downstream mediator of PGE 2 /EP 4 /β-arr1/ Src-mediated signalling, could promote cellular proliferation in PGE 2 -treated PHG. In addition, using the above inhibitor, we did not observe a significant effect in PHG β-arr1-KO mice regardless of PGE 2 treatment (Figure 7) . In summary, inhibition of Src or EGFR blocks PGE 2 /EP 4 receptor-induced mucosal proliferation in PHG, and EP 4 /β-arr1/Src/EGFR signalling contributes to the mucosal proliferation induced by PGE 2 treatment in PHG.
PGE 2 /EP 4 receptor-mediated β-arr1/Src/EGFR complex contributes to mucosal proliferation via Akt activation in PHG We confirmed that the β-arr1/Src/EGFR complex has an important role in PGE 2 /EP 4 receptor-mediated mucosal proliferation in PHG. We hypothesized that Akt is involved in β-arr1-mediated regulation of PGE 2 /EP 4 receptor signalling. Immunostaining and immunoblotting showed that the positive signal of p-Akt, the active form of Akt, was reduced in the mucosa of patients with PHG, which was accompanied by a down-regulation of PCNA ( Figure 8A, C, D) . Furthermore, PVL-treated β-arr1-WT mice treated with PGE 2 showed enhanced expression of p-Akt compared with PVLtreated KO mice ( Figure 8B ). Western blotting analysis of the mucosa of PVL-treated β-arr1-WT and β-arr1-KO mice, with or without PGE 2 treatment, revealed that PGE 2 promotes p-Akt up-regulation via β-arr1, which was abolished by β-arr1 deficiency ( Figure 8E, F) .
PP2, an Src inhibitor, markedly inhibited Akt activation and PCNA levels in PVL-treated β-arr1-WT mice treated with PGE 2 but not in PVL-induced β-arr1-KO mice treated with PGE 2 , possibly because few of the target proteins could be detected in β-arr1-KO PHG mice ( Figure 9A, C, D) . As expected, the EGFR inhibitor AG1478 could inhibit the activation of Akt, block PCNA up-regulation and subsequently decrease the mucosal proliferation mediated by PGE 2 in PHG WT mice ( Figure 9B, E, F) . To demonstrate the definite role of Akt in the pro-proliferative signalling complex, further analysis using the Akt inhibitor VIII (A6730) revealed that A6730 inhibited PCNA up-regulation and Akt activation, but had no effect on Src or EGFR activation in PHG mice treated with PGE 2 (Figure 10 ). These results suggest that active Akt, as a downstream element of the PGE 2 /EP 4 receptor-mediated β-arr1/Src/EGFR complex, contributes to the mucosal proliferation in PHG, and inhibition of Akt activation blocks the mucosal proliferation induced by PGE 2 in PHG. Thus, the PGE 2 /EP 4 receptormediated β-arr1/Src/EGFR complex contributes to mucosal proliferation via Akt activation in PHG.
Discussion
In the current study, the levels of COX-2 and PGE 2 were significantly decreased in the gastric mucosa of patients with PHG and in a mouse model of PHG. The scaffolding cell signalling protein, β-arr1, has been identified as a protein scaffold to link receptors to downstream signalling pathways, such as MAPKs, Src and EGFR (Shukla et al., 2014; Eichel et al., 2016) . We previously revealed that portal hypertension induced ER stress/PUMA-mediated gastric mucosal apoptosis in PHG (Tan et al., 2014) . Moreover, β-arr1 was up-regulated in the process of PHG, which was accompanied by ER stress/PUMA-mediated mucosal apoptosis, while targeted deletion of β-arr1 aggravated ER stress/PUMA-mediated gastric mucosal apoptosis in PHG . In the present study, we examined PVL-induced PHG in β-arr1-WT and β-arr1-KO mice, so as to investigate the effect of β-arr1 on PGE 2 -mediated mucosal proliferation in PHG. Our findings confirmed that COX-1 but not COX-2, accompanied by PGE 2 generation and increased EP 4 receptor levels, was suppressed in the mucosa of patients with PHG and in mice with PHG, and that PGE 2 treatment attenuates mucosal injury and epithelial apoptosis and promotes mucosal proliferation via EP 4 receptors and β-arr1 in mouse PHG.
The EP 4 receptor is a member of the GPCRs family and is the most widely expressed PGE 2 receptor in an organism (Fushimi et al., 2007) . Several studies have revealed that a reduction in the expression of the EP 4 receptor is involved in the pathogenesis of 3% dextran sulfate sodium saltinduced colitis in mice, ischaemia/reperfusion-induced intestinal injury and nonsteroidal anti-inflammatory druginduced gastropathy (Takeuchi et al., 2010; Konya et al., 2013; Nakanishi and Rosenberg, 2013) . EP 4 receptors can recruit β-arr1, which in turn activates Src to initiate the transactivation of EGFR and subsequent downstream Figure 7 Inhibition of Src or EGFR blocks PGE 2 /EP 4 receptor-mediated mucosal proliferation in PHG. (A) The Src inhibitor PP2 (80 nmol per mouse) significantly suppressed PVL-induced p-Src and p-EGFR expression in mice, as determined by western blotting. n = 6 per group. (B) Western blotting revealed that the EGFR inhibitor AG1478 (80 nmol per mouse) suppressed PVL-induced p-EGFR expression in both PGE 2 -treated β-arr1-WT and β-arr1-KO mice under PVL. n = 6 per group. (C) and (D) PCNA-stained images of the groups indicated (brown, ×200, n = 6 per group). (E) and (F) The proliferation index from PCNA staining was analysed as described previously. *P < 0.05 versus β-arr1-WT mice with the vehicle treatment (n = 6 per group). (G) The ratio of densitometry units of the normalized p-EGFR/β-actin was presented from western blotting of (A). n = 6 per group, Bonferroni's comparison post hoc test. *P < 0.05 versus WT mice with vehicle administration. (H) The ratio of densitometry units of the normalized p-Src/β-actin from western blotting of (B). n = 6 per group, Bonferroni's comparison post hoc test. *P < 0.05 versus WT mice with vehicle administration, #P < 0.05 versus WT mice with AG1478 administration.
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signalling via PI3K, ERK1/2, which could restore the activity of cells, proliferation and differentiation in conditions such as papilloma formation and keratinocyte proliferation (Neuschafer-Rube et al., 2004; Chun et al., 2010; Kim et al., 2010) . In the current study, we demonstrated that PGE 2 administration ameliorates the gastric mucosal damage and apoptosis in PHG via the EP 4 receptor and that PGE 2 stimulation of EP 4 receptors induced the formation of a β-arr1/Src/EGFR complex, which resulted in Src activation and the transactivation of EGFR, ultimately promoting Akt activation in PHG. The mechanism by which PGE 2 regulates mucosal apoptosis in PHG warrants further study.
The EGFR and the non-receptor protein tyrosine kinase Src have been implicated in linking a series of GPCRs to Figure 8 Akt activation is involved in PGE 2 /EP 4 receptor-mediated mucosal proliferation in PHG. (A) p-Akt and PCNA expression revealed by immunohistochemical staining (brown, ×400, n = 6 per group). (B) p-Akt expression in the gastric mucosa of PVL-treated β-arr1-WT and β-arr1-KO mice with or without PGE 2 treatment (3 mg·kg À1 ) was evaluated by immunohistochemical staining (brown, ×200, n = 6 per group).
(C) p-Akt expression of uninvolved normal gastric mucosal tissue (from healthy volunteers) and gastropathic mucosal tissue from PHG patients was analysed by western blotting (n = 6 per group). (D) The ratio of densitometry units of the normalized p-Akt/β-actin was represented from western blotting (n = 6 per group, Bonferroni's comparison post hoc test). (E) The expression of p-Akt in the sections of PVL-treated β-arr1-WT and β-arr1-KO mice, with or without PGE 2 treatment (3 mg·kg À1 ), was evaluated by western blotting (n = 6 per group). (F) The ratio of densitometry units of the normalized p-Akt/β-actin from western blotting. *P < 0.05 versus WT mice with vehicle administration. (n = 6 per group, Bonferroni's comparison post hoc test).
downstream signalling cascades, which has an important role in the pathogenesis of numerous diseases, including prostate carcinoma, colorectal cancer, inflammatory diseases and gastrointestinal disorders (Giannoni et al., 2009; Singh et al., 2012; Taniguchi et al., 2013; McCarthy et al., 2014) . The EGFR inhibitor AG1478 and Src inhibitor PP2 significantly
Figure 9
The PGE 2 /EP 4 receptor-mediated β-arr1/Src/EGFR complex contributes to mucosal proliferation via Akt activation in PHG. (A) PP2 treatment (80 nmol per mouse) blocked the upregulation of p-Akt and PCNA in β-arr1-WT mice following PGE 2 administration (3 mg·kg À1 ) and promoted the expression of cleaved caspase-3 in the representative mucosa of β-arr1-WT mice following PGE 2 administration. β-actin was used as the loading control, n = 6 per group. (B) AG1478 treatment (80 nmol per mouse) down-regulated the levels of p-Akt and PCNA in β-arr1-WT mice following PGE 2 administration (3 mg·kg À1 ) and enhanced the expression of cleaved caspase-3 in the mucosa of PVL-treated β-arr1-WT mice with PGE 2 administration. β-actin was used as the loading control, n = 6 per group. (C) and (D) The ratio of densitometry units of the normalized p-Akt/ β-actin and PCNA/β-actin of PP2-treated sections from western blotting. *P < 0.05 versus β-arr1-WT mice with the vehicle treatment. n = 6 per group, Bonferroni's comparison post hoc test. (E) and (F) The ratio of the normalized p-Akt/β-actin and PCNA/β-actin densitometry units. *P < 0.05 versus β-arr1-WT mice with the vehicle treatment (n = 6 per group, Bonferroni's comparison post hoc test).
suppressed a variety of cellular functions, including proliferation, survival and migration (Chun et al., 2010 Akt, blocked PCNA up-regulation and subsequently decreased the mucosal proliferation mediated by PGE 2 in PHG WT mice, without affecting Src activation, β-arr1 and the induction of EP 4 receptors in PHG mice. These results suggest that EGFR, as the downstream mediator of PGE 2 / EP 4 /β-arr1/Src-mediated signalling, could promote Akt activation and cellular proliferation in PHG. Further analysis using the Akt inhibitor VIII suggested that active Akt, as a downstream element of the PGE 2 /EP 4 receptor-mediated β-arr1/Src/EGFR complex, contributes to mucosal proliferation in PHG. Acute and perhaps chronic gastric bleeding along with mucosal erosion and injury are the most important complications of PHG, and a number of pharmacological therapies have been used in an effort to treat gastric bleeding with their effects being predicated on a reduction in portal pressure and gastric blood flow. Propanolol (a β 2 -adrenoceptor ligand), somatostatin and its analogue octreotide have been found to reduce recurrent bleeding in PHG, but at the expense of decreasing mucosal nutrition and oxygenation and their role in the management of PHGassociated bleeding has not been fully assessed (Cubillas and Rockey, 2010) . Endoscopic treatment of PHG bleeding plays a highly limited role in the treatment of PHG because bleeding is always diffuse, and argon coagulation and sclerotherapy are only considered with focal bleeding. Surgical and transjugular intrahepatic portosystemic shunts are both invasive and are associated with substantial morbidity and mortality and would be considered only as a last resort in the management of excessive bleeding . Therefore, in terms of prophylaxis and the management of PHG bleeding, there is little definitive data with which to make recommendations. In our current study, PGE 2 could recruit the β-arr1/Src/EGFR complex to the EP 4 receptor, which could ameliorate mucosal apoptosis and enhance cellular proliferation in PHG. These processes might also prevent mucosal erosion and haemorrhage. Thus, an up-regulation of PGE 2 and its related proliferative signalling elements might be used in primary prophylaxis and for the management of haemorrhage in PHG.
In summary, treatment with PGE 2 resulted in the recruitment of the β-arr1/Src/EGFR complex to the receptor EP 4 , ameliorating mucosal apoptosis and enhancing cellular proliferation in PHG via the Akt/PCNA signalling pathway. These results indicate that β-arr1 regulated PGE 2 /EP 4 receptor-mediated mucosal proliferation by promoting the activation of the Src/EGFR/Akt/PCNA and that this network may represent a potential therapeutic target for PHG.
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http://doi.org/10.1111/bph.13752 Figure S1 PGE2repressed mucosal apoptosisin PHG.(A) PG E2 (PGE2)treatment attenuated the gastric mucosal apoptosis in partial portal vein ligation (PVL)-treated mice by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) staining analysis (green, ×200, n = 6 per group). Cell nuclei (blue) were counterstained with DAPI (4 0 6-diamidino-2-phenylindole dihydrochloride, blue). (B) The apoptotic index was calculated by enumerating apoptotic cells in a minimum of 20 randomly selected fields and dividing the number of TUNEL-positive cells by the total number of cells. Values are expressed as mean ± SEM (n = 6 per group). *P < 0.05 versus sham operation (SO) mice, #P < 0.05 versus PVL mice with PGE2administration. (C), (D), (E) and (F) Quantitative analysis of the normalized EP4/β-actin, PCNA/β-actin, barr1/β-actin and cleaved caspase-3/β-actin ratio, as measured by densitometry scanning of western blotting from Figure F . Values are expressed as mean ± SEM (n = 6 per group). *P < 0.05 versus SO mice, #P < 0.05 versus PVL mice with PGE2administration.
